[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558008":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":25,"locations":28,"responsibleParty":47,"collaborators":25,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":25,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":25,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":25,"overallStatus":31,"whyStopped":25,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Yonsei University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"celecoxib monotherapy","ACTIVE_COMPARATOR","celecoxib \\[400mg, twice a day\\] for 6 months",[13],"Drug: celecoxib monotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"celecoxib and metformin combination","EXPERIMENTAL","celecoxib \\[400mg, twice a day\\] and metformin \\[1g, twice a day\\] for 6 months",[19],"Drug: celecoxib and metformin combination",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Patients will be randomly assigned in a 1:1 ratio to receive celecoxib monotherapy or combination of celecoxib and metformin orally for 6 months: celecoxib \\[400mg, twice a day\\] in arm 1, celecoxib \\[400mg, twice a day\\] and metformin \\[1g, twice a day\\] in arm 2.",[9],null,{"type":22,"name":15,"description":23,"armGroupLabels":27,"otherNames":25},[15],[29],{"facility":30,"status":31,"city":32,"state":25,"zip":33,"country":34,"countryCode":25,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Department of Internal Medicine, Yonsei University College of Medicine","RECRUITING","Seoul","120-752","South Korea",{"type":36,"coordinates":37},"Point",[38,39],126.9784,37.566,{"lat":39,"lon":38},[42],{"name":43,"role":44,"phone":45,"phoneExt":25,"email":46},"TAE IL KIM, MD","CONTACT","82-2-2228-1965","taeilkim@yuhs.ac",{"type":48,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100558008","phase-3-chemopreventive-effect-of-combination-of-celecoxib-and-metformin-in-patients-with-familial-adenomatous-polyposis-100558008",false,"NCT06545526","Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis","The Chemopreventive Effect of Celecoxib Monotherapy Versus Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis: a Pilot Randomized, Open-label, Comparative Study","Inclusion Criteria:\n\n\\- 1. Patients with familial adenomatous polyposis(FAP) who are 20 to 55 years of age.\n\n2\\. FAP patients who have colonic or duodenal polyp. 3. FAP patients who have five or more polyps 2mm or more in diameter in endoscopic examination.\n\nExclusion Criteria:\n\n* 1\\. FAP patients who had a history of colectomy within the previous 12 months or need to undergo colectomy within 8 months after randomization.\n\n  2\\. FAP patients with malignant disease, including colorectal cancer. 3. FAP patients who used NSAIDs (non-steroidal anti-inflammatory drugs) or aspirin three or more times a week within 3 months of randomization.\n\n  4\\. Pregnant or breast-feeding patients. 5. Patients with cardiovascular diseases, peptic ulcer diseases and diabetes. 6. Patients with abnormal results of serum laboratory tests (renal function and liver function test).","ALL","20 Years","55 Years",{"count":60,"type":61},28,"ESTIMATED","INTERVENTIONAL",[64],"PHASE3","Familial adenomatous polyposis (FAP) leads to adenomas and eventual adenocarcinomas in colon and less frequently, duodenum. Chemopreventive strategies have been studied in FAP patients to delay the development of adenomas and cancers. The non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitor have shown the regression of colorectal and duodenal adenomas in FAP patients. However, these drugs showed gastrointestinal damage and cardiovascular risks, and new preventive strategies are needed. Metformin, an anti-diabetic drug, has recently been suggested to have a suppressive effect on tumorigenesis via inhibition of mTOR pathway, and have an inhibitory effect on polyp recurrence after removal of sporadic colorectal polyps. In addition, metformin has a number of potential mechnisms of carciovascular bebefit. We devised a randomized, open-label, comparative study to evaluate the effect of combination of celecoxib and metformin on polyps of colorectum and duodenum in FAP patients.",[67],"Familial Adenomatous Polyposis","2024-08-05",{"date":70,"type":71},"2024-08-09","ACTUAL",{"date":73,"type":61},"2024-08-13",{"date":75,"type":61},"2026-06-30",{"name":5,"class":6},1]